Rovi's EBITDA fell by 2% to €167.2 million, and operating income decreased 5% to €564.6 million from January to September 2024, largely due to reduced COVID...
Rovi shares fell 10.5%, contributing to a 1.9% decline in Spain's pharmaceutical sector. Almirall also dropped 1.2%, while PharmaMar and Grifols rose 22.4% and 1.4%, respectively....